Loading...
•
Mar 31, 2023
Kiniksa Q1 2023 Earnings Report
Reported first quarter 2023 financial results with ARCALYST® net product revenue of $42.7 million.
Key Takeaways
Kiniksa Pharmaceuticals reported first quarter 2023 financial results, highlighted by ARCALYST® net product revenue of $42.7 million. The company increased ARCALYST full-year 2023 net product revenue guidance to $200 - $215 million. They are enrolling the final cohort of KPL-404 Phase 2 rheumatoid arthritis trial with data expected in 1H 2024. Cash reserves are expected to fund operations into at least 2026.
ARCALYST Q1 2023 net product revenue was $42.7 million.
ARCALYST full-year 2023 net product revenue guidance increased to $200 - $215 million, representing ~69% year-over-year growth at the midpoint.
The final cohort of KPL-404 Phase 2 rheumatoid arthritis trial is now enrolling patients; data is expected in 1H 2024.
Cash reserves are now expected to fund operations into at least 2026.
Revenue by Segment
Forward Guidance
Kiniksa increased ARCALYST full-year 2023 net product revenue guidance to $200 - $215 million, representing ~69% year-over-year growth at the midpoint.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...